Skip to main content
See every side of every news story
Published • loading... • Updated

Tempest acquires rights to experimental myeloma treatment

Following positive early data from an ongoing clinical trial, Tempest Therapeutics has exercised an option to obtain rights to develop and commercialize an experimental therapy for myeloma that is being developed by Hebei Senlang Biotechnology. The newly executed option gives Tempest rights to the therapy, which the company is renaming TPST-4903, in all countries outside […]
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

rarecancernews.com broke the news on Monday, November 16, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal